T
Thomas G. Graeber
Researcher at University of California, Los Angeles
Publications - 154
Citations - 25174
Thomas G. Graeber is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Cancer & Melanoma. The author has an hindex of 66, co-authored 144 publications receiving 20409 citations. Previous affiliations of Thomas G. Graeber include University of California & Energy Institute.
Papers
More filters
Journal ArticleDOI
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky,Angel Garcia-Diaz,Daniel Sanghoon Shin,Helena Escuin-Ordinas,Willy Hugo,Siwen Hu-Lieskovan,Davis Y. Torrejon,Gabriel Abril-Rodriguez,Salemiz Sandoval,Lucas Barthly,Justin Saco,Blanca Homet Moreno,Riccardo Mezzadra,Bartosz Chmielowski,Kathleen Ruchalski,I. Peter Shintaku,Phillip J. Sanchez,Cristina Puig-Saus,Grace Cherry,Elizabeth Seja,Xiangju Kong,Jia Pang,Beata Berent-Maoz,Begoña Comin-Anduix,Thomas G. Graeber,Paul C. Tumeh,Ton N. Schumacher,Roger S. Lo,Antoni Ribas +28 more
TL;DR: Acquired resistance to PD-1 blockade immunotherapy in patients with melanoma was associated with defects in the pathways involved in interferon-receptor signaling and in antigen presentation.
Journal ArticleDOI
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Thomas G. Graeber,Cynthia Osmanian,Tyler Jacks,David E. Housman,Cameron J. Koch,Scott W. Lowe,Scott W. Lowe,Amato J. Giaccia +7 more
TL;DR: It is proposed that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53mutations.
Journal ArticleDOI
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases.
Jason Lloyd-Price,Jason Lloyd-Price,Cesar Arze,Ashwin N. Ananthakrishnan,Melanie Schirmer,Melanie Schirmer,Julian Avila-Pacheco,Tiffany W. Poon,Elizabeth Andrews,Nadim J. Ajami,Kevin S. Bonham,Kevin S. Bonham,Colin J. Brislawn,David Casero,Holly Courtney,Antonio Gonzalez,Thomas G. Graeber,A. Brantley Hall,Kathleen Lake,Carol J. Landers,Himel Mallick,Himel Mallick,Damian R. Plichta,Mahadev Prasad,Gholamali Rahnavard,Gholamali Rahnavard,Jenny S. Sauk,Dmitry Shungin,Dmitry Shungin,Yoshiki Vázquez-Baeza,Richard A. White,Jonathan Braun,Lee A. Denson,Lee A. Denson,Janet K. Jansson,Rob Knight,Subra Kugathasan,Dermot P.B. McGovern,Joseph F. Petrosino,Thaddeus S. Stappenbeck,Harland S. Winter,Clary B. Clish,Eric A. Franzosa,Hera Vlamakis,Ramnik J. Xavier,Ramnik J. Xavier,Ramnik J. Xavier,Curtis Huttenhower,Curtis Huttenhower +48 more
TL;DR: It is demonstrated that periods of disease activity were also marked by increases in temporal variability, with characteristic taxonomic, functional, and biochemical shifts, and integrative analysis identified microbial, biochemical, and host factors central to this dysregulation.
Journal ArticleDOI
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos,Yogindra Persaud,Manickam Janakiraman,Xiangju Kong,Charles Ng,Gatien Moriceau,Hubing Shi,Mohammad Atefi,Bjoern Titz,May Tal Gabay,Maayan Salton,Kimberly B. Dahlman,Madhavi Tadi,Jennifer A. Wargo,Keith T. Flaherty,Mark C. Kelley,Tom Misteli,Paul B. Chapman,Jeffrey A. Sosman,Thomas G. Graeber,Antoni Ribas,Roger S. Lo,Neal Rosen,David B. Solit +23 more
TL;DR: The model that inhibition of ERK signalling by RAF inhibitors is dependent on levels of RAS–GTP too low to support RAF dimerization is supported and a novel mechanism of acquired resistance in patients is identified: expression of splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.